Table 1 Comparison of MCC promoter methylation with CDKN2A promoter methylation, MLH1 protein expression, MSI and other clinicopathologic variables in 103 clinicopathologic stage C colon cancer patients

From: Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer

  MCC Methylated MCC Unmethylated Total number of patients P
CDKN2A
 Methylated 27 (79.4) 7 (20.6) 34  
 Unmethylated 27 (39.1) 42 (60.9) 69 0.0001
MLH1 expression
 Negative 13 (72.2) 5 (27.8) 18  
 Positive 41 (48.2) 44 (51.8) 85 0.0642
MSI-H 17 (68.0) 8 (32.0) 25  
MSI-L/MSS 37 (48.7) 39 (51.3) 76 0.0934
Female 21 (52.5) 19 (47.5) 40  
Male 33 (52.4) 30 (47.6) 63 0.9906
Proximal colon 48 (61.5) 30 (38.5) 78  
Splenic flexure and descending colon 6 (24.0) 19 (76.0) 25 0.0011
Low–average grade 21 (40.4) 31 (59.6) 52  
High grade 33 (64.7) 18 (35.3) 51 0.0135
1–3 nodes 32 (45.1) 39 (54.9) 71  
4 nodes 22 (68.8) 10 (31.2) 32 0.026
Apical node involved
 Yes 7 (70.0) 3 (30.0) 10 0.2416
 No 47 (50.5) 46 (49.5) 93  
Veins involved
 Yes 13 (61.9) 8 (38.1) 21  
 No 41 (50.0) 41 (50.0) 82 0.3297
Tumor size
 <5 cm 23 (46.9) 26 (53.1) 49 0.288
5 cm 31 (57.4) 23 (42.6) 54  
  1. Abbreviations: MCC, mutated in colorectal cancer; MSI-H, high microsatellite instability; MSI-L, low microsatellite instability; MSS, microsatellite stable.